

INOVIO PHARMACEUTICALS (INO)  
HEALTH CARE - DRUGS - MEDICAL-BIOMED/GENETICS

Company Description

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV) cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Latest Price <i>as of()</i> <b>\$1.37</b> <b>()</b> <b>()</b>	Prior Close \$1.37	Open	Volume	Annual Div. \$0.00	Mkt Cap (\$Mil) 50	Zack Rank - Buy 	Zacks Sector Rank Top 50% (8 out of 16)	Style Scores Value: Growth: Monumentum: VGM:
52 Week Range \$1.30 <span style="float:right">\$12.33</span>  07/15/2025 <span style="float:right">07/26/2024</span>	Day Range 		Avg Volume 3,163,019	Div. Yield 0.00%	Beta 1.31	Zacks Recommendation Neutral (Since 03/11/24)	Zacks Sub-Industry Rank Top 35% (84 out of 246)	

Total Return	INO	SP 500
% Total Return MTD	-34.15%	1.02%
% Total Return QTD	-34.15%	1.02%
% Total Return YTD	-26.78%	7.17%
% Total Return 1 Year	-87.88%	12.51%
% Total Return 3 Year	-93.55%	71.19%
% Total Return 5 Year	-99.59%	113.33%

Volume	
Avg Daily Volume	3,163,019
Shares Outstanding	36.67
Avg Volume / Shares Out	8.62%

Broker Recommendation	
Broker Rating (Avg)	1.86
Upgrades (4 weeks)	
Downgrades (4 weeks)	

Target Price	
Price Target (mean)	\$7.14
Target Up/Down Potential	4.21%

Holders	
Held by Insiders	2.30%
Held by Institutions	26.79%
Zacks Institutional Transaction Rank	50.0

Price and Earnings Chart



Insider Trading Stats

Net % Chg Holdings- Last 12 wks	
# of Inside Buyers - Last 12 wks	
# of Inside Sellers - Last 12 wks	
Zacks Insider Rank	

Dividends	
Annualized Div Growth - 3 Years	-
Annualized Div Growth - 5 Years	-

# of Dividend Increases - 3 Years	0
# of Dividend Increases - 5 Years	0

Last Dividend Amount	\$0.00
----------------------	--------

Next Dividend Amount	-
Next Dividend Ex-Date	-

Zacks Earnings & Dividend Score	
---------------------------------	--

Actuals

Earnings Per Share	Actual	Y/Y %
Last Quarter (03/2025)	-0.51	61.07%
Prior Quarter (12/2024)	-0.69	
Last Year (12/2024)	-4.05	27.94%
Prior Year (12/2023)	-5.62	59.99%

Sales

Last Quarter (03/2025)	00	-67.50%
Prior Quarter (12/2024)	00	13.53%
Last Year (12/2024)	00	-73.83%
Prior Year (12/2023)	01	-91.89%

Long Term Growth Rate

EPS - 5 Year	
Sales - 5 Year	

Estimates

Earnings Per Share	Estimate	Y/Y %
Current Quarter (06/2025)	-0.63	47.27%
Next Quarter (09/2025)	-0.46	48.88%
Current Year (12/2025)	-1.96	51.86%
Next Year (12/2026)	-1.57	20.16%

Sales

Current Quarter (06/2025)	00	-50.50%
Next Quarter (09/2025)	00	-50.00%
Current Year (12/2025)	00	-45.66%
Next Year (12/2026)	15	12644.02%

Long Term Growth Rate

EPS - 3 to 5 Year Estimate	
EPS - 3 to 5 Year - 1stDev	

Key Ratio Data

Valuation	INO	Syr Med
Price / Earnings (F12M)	-0.78%	-2.21%
PEG Ratio (F12M)	-0.02%	
Price / Book Value (TTM)	0.98%	1.86%

Margins (TTM)

Gross Margin	100.00%	100.00%
Net Margin - BNRI	-	
	35071.83%	

Leverage

Long Term Debt/Equity		
Total Debt / Capital		4.13%
Assets to Equity	127.40%	137.95%

Return

Return on Equity	-136.93%	-82.19%
Return on Assets	-89.99%	-61.11%
Return on Capital	-136.93%	